The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations
Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor. Our study aimed to assess the potential interaction of daclatasvir with metformin pharmacokinetics and pharmacodynamics at two metformin doses. T...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ain Shams University
2022-12-01
|
| Series: | Archives of Pharmaceutical Sciences Ain Shams University |
| Subjects: | |
| Online Access: | https://aps.journals.ekb.eg/article_281273.html |
| _version_ | 1797853136654696448 |
|---|---|
| author | Mohamed Raslan Lamia Elwakeel Sara Shahin |
| author_facet | Mohamed Raslan Lamia Elwakeel Sara Shahin |
| author_sort | Mohamed Raslan |
| collection | DOAJ |
| description | Renal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor. Our study aimed to assess the potential interaction of daclatasvir with metformin pharmacokinetics and pharmacodynamics at two metformin doses. Twenty subjects were randomized in a two-period crossover study. The subjects received metformin 500 mg twice daily either alone (R1) or with daclatasvir 60 mg once daily (T1), followed by 1000 mg metformin twice daily either alone (R2) or with daclatasvir 60 mg once daily (T2). Metformin Cmax was higher in T1 and T2 than in R1 and R2 by 12% and 11%, respectively, with a geometric mean ratio (GMR) of 1.12 (90% CI: 0.98-1.26) and 1.12 (90% CI: 0.86-1.36), respectively. Renal clearance (Clr) was lower in T1and T2 compared to R1 and R2 by 15% and 11%, with a GMR of 0.85 (0.68-1.02) and 0.89 (0.69-1.09), respectively. The differences from baseline glucose level (ΔG %) and the area under the Δ G%-time curve (Δ AUG %) were higher for the 500 mg dose of metformin with daclatasvir (p < 0.05). Daclatasvir slightly altered the pharmacokinetics of metformin with a minor alteration of pharmacodynamics of the 500 mg dose. |
| first_indexed | 2024-04-09T19:45:44Z |
| format | Article |
| id | doaj.art-a997a406d4c749fbae19ed2948674dea |
| institution | Directory Open Access Journal |
| issn | 2356-8380 2356-8399 |
| language | English |
| last_indexed | 2024-04-09T19:45:44Z |
| publishDate | 2022-12-01 |
| publisher | Ain Shams University |
| record_format | Article |
| series | Archives of Pharmaceutical Sciences Ain Shams University |
| spelling | doaj.art-a997a406d4c749fbae19ed2948674dea2023-04-03T20:27:49ZengAin Shams UniversityArchives of Pharmaceutical Sciences Ain Shams University2356-83802356-83992022-12-016210.21608/APS.2022.153765.1096The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulationsMohamed Raslan0Lamia Elwakeel1https://orcid.org/0000-0003-0250-1709Sara Shahin2https://orcid.org/0000-0001-5295-6926Department of Clinical Research and Bioanalysis, Drug Research Center, Cairo, EgyptDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, EgyptDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, EgyptRenal Organic Cation Transporter 2 (OCT2) plays a major role in metformin elimination. Daclatasvir, a Direct-Acting Antiviral (DAA), is an OCT2 inhibitor. Our study aimed to assess the potential interaction of daclatasvir with metformin pharmacokinetics and pharmacodynamics at two metformin doses. Twenty subjects were randomized in a two-period crossover study. The subjects received metformin 500 mg twice daily either alone (R1) or with daclatasvir 60 mg once daily (T1), followed by 1000 mg metformin twice daily either alone (R2) or with daclatasvir 60 mg once daily (T2). Metformin Cmax was higher in T1 and T2 than in R1 and R2 by 12% and 11%, respectively, with a geometric mean ratio (GMR) of 1.12 (90% CI: 0.98-1.26) and 1.12 (90% CI: 0.86-1.36), respectively. Renal clearance (Clr) was lower in T1and T2 compared to R1 and R2 by 15% and 11%, with a GMR of 0.85 (0.68-1.02) and 0.89 (0.69-1.09), respectively. The differences from baseline glucose level (ΔG %) and the area under the Δ G%-time curve (Δ AUG %) were higher for the 500 mg dose of metformin with daclatasvir (p < 0.05). Daclatasvir slightly altered the pharmacokinetics of metformin with a minor alteration of pharmacodynamics of the 500 mg dose.https://aps.journals.ekb.eg/article_281273.htmlmetformindaclatasviroct2pharmacokineticspharmacodynamicsmcmc |
| spellingShingle | Mohamed Raslan Lamia Elwakeel Sara Shahin The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations Archives of Pharmaceutical Sciences Ain Shams University metformin daclatasvir oct2 pharmacokinetics pharmacodynamics mcmc |
| title | The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations |
| title_full | The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations |
| title_fullStr | The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations |
| title_full_unstemmed | The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations |
| title_short | The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations |
| title_sort | effect of oct 2 inhibitor daclatasvir on metformin pharmacokinetics and pharmacodynamics at two dose levels a bayesian approach using markov chain monte carlo simulations |
| topic | metformin daclatasvir oct2 pharmacokinetics pharmacodynamics mcmc |
| url | https://aps.journals.ekb.eg/article_281273.html |
| work_keys_str_mv | AT mohamedraslan theeffectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations AT lamiaelwakeel theeffectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations AT sarashahin theeffectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations AT mohamedraslan effectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations AT lamiaelwakeel effectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations AT sarashahin effectofoct2inhibitordaclatasvironmetforminpharmacokineticsandpharmacodynamicsattwodoselevelsabayesianapproachusingmarkovchainmontecarlosimulations |